Literature DB >> 11860783

[A case-control study on the relationship between abnormal homocysteine metabolism and essential hypertension].

S Zhan1, Y Gao, X Yin, Y Huang, Y Hu, L Li.   

Abstract

OBJECTIVE: To examine the relationship between abnormal homocysteine metabolism and essential hypertension in a Chinese population, a community-based case-control study was conducted.
METHODS: 127 essential hypertensive patients aged 35 to 75 were randomly selected from a community. Another 170 control subjects with blood pressure < 140/90 mmHg were selected from the same community. Serum homocysteine was determined using HPLC. Folate and vitamin B(12) were measured by radioimmunoassay. MTHFR genotypes were identified by PCR and restriction fragment length polymorphism analysis with Hinf I digestion.
RESULTS: After adjusting for age and sex, the mean homocysteine level was 10.56 micromol/L for hypertensive patients and 10.34 micromol/L for controls (F = 0.234, P = 0.63). No association between either SBP or DBP and Hcy concentration was found in subjects without anti-hypertensive medications. The prevalence of homozygousity for thermolabile MTHFR variant for this population was 13.1%, and the mutant allele frequency was 38.7%. There was no significant difference on genotype distributions and the mutant allele frequency for the two studied groups. However, the concentrations of folate and B(12) for the hypertensive subjects were generally higher than the controls.
CONCLUSIONS: The present study did not discover that the elevation of Hcy levels or MTHFR mutation were independent risk factors for essential hypertension. The higher folate and B(12) in the hypertensive subjects might contribute to a lower risk.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11860783

Source DB:  PubMed          Journal:  Zhonghua Liu Xing Bing Xue Za Zhi        ISSN: 0254-6450


  7 in total

Review 1.  Methylenetetrahydrofolate Reductase Polymorphism (rs1801133) and the Risk of Hypertension among African Populations: A Narrative Synthesis of Literature.

Authors:  Sihle E Mabhida; Babu Muhamed; Jyoti R Sharma; Teke Apalata; Sibusiso Nomatshila; Lawrence Mabasa; Mongi Benjeddou; Charity Masilela; Khanyisani Ziqubu; Samukelisiwe Shabalala; Rabia Johnson
Journal:  Genes (Basel)       Date:  2022-04-01       Impact factor: 4.141

2.  Evidence on the causal link between homocysteine and hypertension from a meta-analysis of 40 173 individuals implementing Mendelian randomization.

Authors:  Liwan Fu; Ya-Nan Li; Dongmei Luo; Shufang Deng; Baihui Wu; Yue-Qing Hu
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-11-25       Impact factor: 3.738

Review 3.  Associations of MTHFR gene polymorphisms with hypertension and hypertension in pregnancy: a meta-analysis from 114 studies with 15411 cases and 21970 controls.

Authors:  Boyi Yang; Shujun Fan; Xueyuan Zhi; Yongfang Li; Yuyan Liu; Da Wang; Miao He; Yongyong Hou; Quanmei Zheng; Guifan Sun
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

4.  Associations of plasma homocysteine levels with peripheral systolic blood pressure and noninvasive central systolic blood pressure in a community-based Chinese population.

Authors:  Mohetaboer Momin; Fangfang Fan; Jianping Li; Xianhui Qin; Jia Jia; Litong Qi; Yan Zhang; Yong Huo
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

Review 5.  Association Between MTHFR Polymorphisms and the Risk of Essential Hypertension: An Updated Meta-analysis.

Authors:  Hao Meng; Shaoyan Huang; Yali Yang; Xiaofeng He; Liping Fei; Yuping Xing
Journal:  Front Genet       Date:  2021-11-26       Impact factor: 4.599

6.  Association of ALDH2 rs671 and MTHFR rs1801133 polymorphisms with hypertension among Hakka people in Southern China.

Authors:  Heming Wu; Qingyan Huang; Zhikang Yu; Zhixiong Zhong
Journal:  BMC Cardiovasc Disord       Date:  2022-03-27       Impact factor: 2.298

7.  APOE Genetic Polymorphism rs7412 T/T Genotype May Be a Risk Factor for Essential Hypertension among Hakka People in Southern China.

Authors:  Hui Rao; Heming Wu; Zhikang Yu; Qingyan Huang
Journal:  Int J Hypertens       Date:  2022-09-14       Impact factor: 2.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.